Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423756 · ClinicalTrials.gov registry record · NA
INSPIRE Trial for Skin and Soft Tissue Infections
A NA study, sponsored by Harvard Pilgrim Health Care.
- Completed
- Registry status
- NA
- Development phase
- 118,562
- Enrollment target
NCT05423756: Completed NA study, sponsored by Harvard Pilgrim Health Care.
NCT05423756 is a NA study that has completed, run by Harvard Pilgrim Health Care. The registered enrollment target is 118,562 participants, above the 1,402-participant average among 58,714 other NA trials with a reported enrollment target (8357% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423756, a NA study, has completed, sponsored by Harvard Pilgrim Health Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 118,562 participants
- Enrollment target
Study Summary
The INSPIRE Skin and Soft Tissue Infection trial is a cluster-randomized controlled trial of HCA Healthcare hospitals comparing routine empiric antibiotic stewardship practices with real-time, precision medicine computerized physician order entry (CPOE) smart prompts providing the probability that a non-critically ill adult admitted with skin and soft tissue infection is infected with a resistant pathogen. Note: enrolled "subjects" represent 102 individual HCA Healthcare hospitals that have been randomized into 92 clusters. Hospitals were grouped into the same randomization cluster if they shared campuses or antibiotic stewardship staff.
Primary Outcome
Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Extended-spectrum days-of-therapy per empiric day is defined as the summed number of different extended-spectrum antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute t
Interventions
- OTHER Arm 1: Routine Care
- OTHER Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118,562 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2024-05-09 |
| Phase | NA |
What the finished NCT05423756 record still lists
NCT05423756 is an interventional study that assigns participants to a tested intervention. Its 118,562 participants enrollment target places it among the larger protocols in the corpus, above the 1,402-participant average among 58,714 other NA trials with a reported enrollment target (8357% higher).
The record links to 0 conditions, and to 2 interventions - of which Arm 1: Routine Care is the first listed.
NCT05423756 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05423756 about?
NCT05423756 is a clinical study titled "INSPIRE Trial for Skin and Soft Tissue Infections". The INSPIRE Skin and Soft Tissue Infection trial is a cluster-randomized controlled trial of HCA Healthcare hospitals comparing routine empiric antibiotic stewardship practices with real-time, precision medicine computerized physician order entry (CPOE) smart prompts providing the probability that a...
What is the current status of trial NCT05423756?
This trial is currently completed. It is a NA study. The enrollment target is 118,562 participants. The study started on 2023-01-01. Estimated completion is 2024-05-09.
What interventions are being tested in trial NCT05423756?
The interventions under investigation include: Arm 1: Routine Care (OTHER), Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection (OTHER).
Who is sponsoring clinical trial NCT05423756?
This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05423756's enrollment target sits among peer trials
118,562 2nd of 2000 the highest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06251323 · 119,680 participants · NA
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
- NCT03897374 · 120,000 participants
Strategic Targeting for Optimal Prevention of Cancer
- NCT06608758 · 120,000 participants
End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI